Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.34 |
| ▸ | DRD3 | P35462 | 9/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129028 | 0.82 | SIGMAR1 (0.43) | DRD2DRD3DRD4CYP17A1SIGMAR1 | |
| SCHEMBL1129017 | 0.76 | SIGMAR1 (0.39) | DRD2DRD3DRD4CYP17A1SIGMAR1 | |
| SCHEMBL3616103 | 0.74 | CYP19A1 (0.45) | CYP17A1 | |
| SCHEMBL25186921 | 0.73 | DRD2 (0.38) | DRD2DRD3CHRM1DRD4HTR1D | |
| SCHEMBL12060813 | 0.73 | CYP19A1 (0.37) | CYP17A1 | |
| SCHEMBL1129300 | 0.72 | KDM1A (0.40) | DRD2DRD3DRD4CYP17A1 | |
| SCHEMBL23714864 | 0.70 | DRD2 (0.36) | DRD2DRD3CHRM1DRD4HTR1D | |
| SCHEMBL3464936 | 0.70 | CYP19A1 (0.35) | DRD2DRD3CHRM1DRD4HTR1D | |
| SCHEMBL743744 | 0.69 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL1129324 | 0.68 | KDM1A (0.46) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-1896481-B1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | DRD2 2953/4885DRD3 1977/4885CHRM1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.